Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab vs Tocilizumab Single-Dose PD/Safety in RA
NCT02097524Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2014
- Primary completion
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sarilumab in rheumatoid arthritis (RA) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Pharmacodynamic parameters at 4 weeks. Started Mar 2014; status: completed.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02097524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097524.